BUSINESS BRIEF

The company has grown organically and through joint ventures and acquisitions, leveraging the resources of its former parent company. It benefited from the previous rounds of capital raising done at the group level, where both strategic and financial investors actively committed to support the growth of the group. The co. has developed biosimilar versions of molecules, in the areas of oncology, cardiovascular, anemia, autoimmune disorders and, for which the patent protection of the originator drug is either not valid for India and certain developing markets or is expected to expire worldwide. With the outbreak of the COVID-19 pandemic, effective treatments are urgently needed which integrate the management of COVID19 induced inflammation and coagulopathies. Our unique therapeutic proposal is to repurpose our proprietary combination of our clinically validated biosimilars for effective COVID19 management that act against overt inflammation, coagulation leading to microthrombosis and maintenance of normal levels of blood oxygen saturation by supporting effective RBC production and restoration of hypoxemic conditions through combinatorial dosage of four products to address the dynamic COVID19 drug market opportunity for further development scale up and completion of Phase I and Phase II clinical trials.